February 28, 2022

Big Pharma May Embrace M&A to Recoup Billions After US Drug Patents Expire

Americas CRO Mark Williams shares insights with S&P Global on how big pharma is embracing M&A this year amidst the pandemic recovery.

Contacts

Media Relations
Marta Carraro

Vice President, Communications

212.367.6162

[email protected]

Investor Relations
Jennifer Percy

Senior Vice President, Finance & Treasury

651.632.4009

[email protected]

You may also like:

Three Things to Know When Taking a Public Company Private

CEO Rusty Wiley writes about the surge in take-private deals and how technology can help, especially when it comes to managing outreach and pipeline.

Forbes
US PE Firm Looks at Lukoil Asset as Sanctions Bite; Tikehau-backed Mecachrome Takes Flight with Rossi Aero

Datasite's September Deal Forecaster highlights which sector is expected to see the most global M&A activity in the coming months.

Global M&A Specialist Opens Manchester Office

EMEA CRO Merlin Piscitelli and VP of Sales Jon Hughes discuss Datasite's newest office in Manchester.